BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 28655712)

  • 1. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
    Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
    Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
    Deuker MM; Marsh Durban V; Phillips WA; McMahon M
    Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer.
    Clarke PA; Roe T; Swabey K; Hobbs SM; McAndrew C; Tomlin K; Westwood I; Burke R; van Montfort R; Workman P
    Oncogene; 2019 Jun; 38(25):5076-5090. PubMed ID: 30905967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation.
    Gonzalez-Del Pino GL; Li K; Park E; Schmoker AM; Ha BH; Eck MJ
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34470822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.
    Chen W; Park JI
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834284
    [No Abstract]   [Full Text] [Related]  

  • 7. Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
    Kan G; Wang Z; Sheng C; Chen G; Yao C; Mao Y; Chen S
    Adv Sci (Weinh); 2021 May; 8(10):2004344. PubMed ID: 34026451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p21-activated kinase 1 (PAK1) can promote ERK activation in a kinase-independent manner.
    Wang Z; Fu M; Wang L; Liu J; Li Y; Brakebusch C; Mei Q
    J Biol Chem; 2013 Jul; 288(27):20093-9. PubMed ID: 23653349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies.
    Hicks HM; Nassar VL; Lund J; Rose MM; Schweppe RE
    Cancer Biol Ther; 2024 Dec; 25(1):2332000. PubMed ID: 38521968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of RAF dimers: it takes two to tango.
    Cook FA; Cook SJ
    Biochem Soc Trans; 2021 Feb; 49(1):237-251. PubMed ID: 33367512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
    Pratilas CA; Taylor BS; Ye Q; Viale A; Sander C; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4519-24. PubMed ID: 19251651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway.
    Weatherdon L; Stuart K; Cassidy M; de la Gándara AM; Okkenhaug H; Muellener M; Mckenzie G; Cook SJ; Gilley R
    Biochem J; 2024 Mar; 481(6):405-422. PubMed ID: 38381045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis.
    Yuan J; Ng WH; Tian Z; Yap J; Baccarini M; Chen Z; Hu J
    Sci Signal; 2018 Oct; 11(554):. PubMed ID: 30377225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
    Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
    J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β-catenin-mutated tumors.
    Kiga M; Nakayama A; Shikata Y; Sasazawa Y; Murakami R; Nakanishi T; Tashiro E; Imoto M
    Sci Rep; 2015 Feb; 5():8155. PubMed ID: 25640451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
    Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
    Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition.
    Ring KL; Yates MS; Schmandt R; Onstad M; Zhang Q; Celestino J; Kwan SY; Lu KH
    Int J Gynecol Cancer; 2017 Jun; 27(5):854-862. PubMed ID: 28498246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live-cell target engagement of allosteric MEKi on MEK-RAF/KSR-14-3-3 complexes.
    Marsiglia WM; Chow A; Khan ZM; He L; Dar AC
    Nat Chem Biol; 2024 Mar; 20(3):373-381. PubMed ID: 37919548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based De Novo Design for the Discovery of Miniprotein Inhibitors Targeting Oncogenic Mutant BRAF.
    Ham JM; Kim M; Kim T; Ryu SE; Park H
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants.
    Yuan J; Ng WH; Lam PYP; Wang Y; Xia H; Yap J; Guan SP; Lee ASG; Wang M; Baccarini M; Hu J
    Oncogene; 2018 Oct; 37(43):5719-5734. PubMed ID: 29930381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.